Skip to main content
Premium Trial:

Request an Annual Quote

ParAllele to Collaborate with Baylor in Congenital Heart Disease Study

NEW YORK, July 29 - Parallele BioScience and Baylor College of Medicine are collaborating on genetic studies of SNPs for certain congenital heart abnormalities, Parallele said today.

 

Under the agreement, Parallele will work with John Belmont of Baylor's cardiovascular genetics clinic, using its SNP genotyping technology to scan candidate genes for mutations for left ventricular outflow tract obstruction, a group of heart abnormalities that can either lead to death in newborns or cause heart valve infections or degenerations later on, the company said.

 

ParAllele will design custom reagents for the experiments, and will use over a thousand samples from patients and families that Baylor researchers have collected.

 

The project is being funded by an NIH grant awarded to Baylor.

 

ParAllele and Baylor have also collaborated on the International HapMap project.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.